CD274 and neoplasm: Additionally, among patients with any tumor PD-L1 expression and bTMB of ≥16 (bTMB clinical trial assay (CTA); Foundation Medicine, Inc, Cambridge, MA), patients given atezolizumab had longer PFS than patients given chemotherapy (HR, 0.55; 95% CI, 0.33, 0.92), suggesting a cooperative predictive value between these independent biomarkers18.